This is an old revision of this page, as edited by Delldot (talk | contribs) at 02:03, 9 January 2007 (copy edit, +cat). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 02:03, 9 January 2007 by Delldot (talk | contribs) (copy edit, +cat)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)Norepinephrine reuptake inhibitors (NRIs), also known as noradrenaline reuptake inhibitors (NARIs), are compounds that elevate the extracellular level of the neurotransmitter norepinephrine in the central nervous system by inhibiting its reuptake from the synaptic cleft into the presynaptic neuronal terminal. The drugs inhibit the class of neurotransmitter transporters known as norepinephrine transporters. They have virtually no action at other monoamine transporters.
List of NRIs
- Atomoxetine (Strattera)
- Reboxetine (Edronax)
- Viloxazine (Vivalan)
- Maprotiline (Ludiomil)
Strattera is available in the United States and is indicated by the Food and Drug Administration (FDA) for the treatment of ADD and ADHD. Off-label uses include the treatment of depression and anxiety.
Reboxetine, unavailable in the United States and Canada, has been found to be effective at combating depression.
This medical treatment–related article is a stub. You can help Misplaced Pages by expanding it. |